As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Media center

Learn more about the recent accomplishments of Genopole’s laboratories, businesses, researchers and entrepreneurs.
Genopole Media Center Genopole Media Center
Key figures
  • +1000

    successful projects

  • 2351

    direct jobs

  • 77


  • 18


Media center

Press Release

Find our latest press releases


Algentech: High-Yield Molecular Farming Of Industrial Ingredients In Plant Chloroplasts

22 juin 2021 – Algentech, a Genopole-accredited French company, has achieved a world's first with its disruptive technology . The company's patented method enables the production of proteins and nucleic acids in plant chloroplasts.

Eu|bic certification

Genopole earns EU|BIC certification

5 décembre 2020 The European Commission's European Business Network (EBN) voted unanimously to certify Genopole as a European Union | Business and Innovation Center (EU|BIC), thus recognizing France's leading biocluster as a key contributor to R&D and Innovation in Genomics in France and Europe.

Covid illustration CP

Enalees announces clinical trial for a COVID-19 test

16 septembre 2020 – C4Diagnostics, Bertin Technologies and Enalees announced the launch of a prospective clinical trial for BEC-SARS-CoV-2 for humans, a rapid, point-of-care diagnostic for COVID-19.


A Friendly Takeover Bid Initiated by OncoDNA on IntegraGen

July 09, 2020 This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies would enable to offer a complete solution that combines oncology laboratory testing and software solutions which will benefit the treatment of patients with advanced cancer.

Cellules bleues fond parme

AB Science : masitinib’s potential mode of action in Alzheimer’s Disease

July 08, 2020 – AB Science SA announced the publication of preclinical study results with masitinib in Alzheimer’s disease entitled, ‘Effects of chronic masitinib treatment in APPPS1dE9 transgenic mice modeling Alzheimer’s disease’.

Rapport Activité 2019

Ÿnsect obtains market approval for an insect-based fertilizer

17 juin 2020 – Ÿnsect has just gained approval for its natural insect fertilizer “ŸnFrass” issued by ANSES, the French Agency for Food, Environmental and Occupational Health & Safety. Ÿnsect thus becomes the first company in the world to obtain certification and marketing approval for a natural insect-based fertilizer.

Pharnext - Prescribed Drugs

Pharnext – A novel strategy to rapidly reposition drugs using existing COVID-19 clinical data

23 mars 2020 – Pharnext annonce l’identification de 97 médicaments fréquemment prescrits, au moyen de sa plateforme de Pleotherapy, comme candidats potentiels au repositionnement dans le traitement du COVID-19.

Integragen - high throughput sequencing

IntegraGen renews its agreement with the Institut Pasteur

11 mars 2020 – IntegraGen announces the renewal of its partnership agreement with the Institut Pasteur until December 2021 related to high-throughput sequencing operations for microbiology activities carried out at the Institut Pasteur

Algentech-crispr cas9

Algentech Granted US Patent For A Key Genome Editing Technology

16 janvier 2020- Algentech annonce la délivrance d'un brevet clé dans le domaine de l'édition du génome par l'Office des brevets des États-Unis

View all >
Media center


Find our latest publications

Press Contact

Contact us!

You would like information on Genopole, conduct an interview, visit the campus …

Contact us
With the support from